Join our free community, The Women’s Peptide Collective, click the Skool link to become a member and to connect, learn, and collaborate. https://www.skool.com/womens-peptide-collective-9663 Go to https://thepeptique.com/ to get all your research peptides .As a loyal listener use the discount code POD15 to get 15% off the entire line of products. Have questions? Feel free to reach out to me: tarawest@westwellnessatx.com Want the free peptide guide? Email me tarawest@westwellnessatx.com and comment Guide and I'll shoot it right over! Follow me on instagram AND TikTOk @westwellnessatx Stay in touch add your email to the list! https://form.jotform.com/25336471779006 In this episode,we dive into the rapidly changing research peptide landscape, discussing regulatory uncertainty, high-risk payment processing challenges, and emerging industry shifts. Learn what’s driving these changes and what they could mean for the future of peptide access and innovation.
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
Transcript
From the show. Tap a time to play from there.
All right, welcome back, everyone. Today was another day where I started to record and realized, I don't even know what point I got to all the way to the end of the episode and realized that my computer had died. And anyway, this is the second week in a row that's happened to me. So I'm kind of glad that happened because after I recorded the first time, I decided to restructure the way that this episode was going to go. And normally I have very detailed notes and bullet points, and I'm kind of following that and sticking with it.
And I really think I'm just going to. I'm going to have more of just kind of a casual conversation regarding this particular topic. And what prompted me to do this is all the inquiries that I received from you guys on a pretty consistent basis. And so the things that we're going to discuss today is really kind of centered around the direction of the research peptide movement. And for those of you who are new to this whole world, I want to kind of break it down because I assume a lot, that my audience
knows a lot, and a lot of you do. So for those of you who have been in this space for a while, I apologize if this seems very basic information. But for those of you who are new, I think it's super important. We have three categories of how these peptides are broken down. We have the pharmaceutical level. Okay? These are the Eli Lillys of the world, the Norvo Nordisk, Anova Nordisk, those types of big companies that primarily put out GLPs and things like that, which is where a lot of the controversy
of all this stuff has started. And I'm going to go into that in just a minute. But then we have the compounding pharmacies, and this is where these products that don't necessarily have, like, patents on them or whatnot, which is what is the conversation regarding what RFK recently said, which we're also going to go to, kind of centers around where you can go to a doctor, they can write you a script for a. A certain type of peptide compounded, and then that compounding
pharmacy will create that for you. But it's not coming from big pharma. And let me back up. The big Pharma, obviously, the GLPs in particular, you have to have a prescription for those. You still have to go through a doctor, but they're getting released through the big pharmaceutical companies. And some of these other ones are getting released through compounding pharmacies. And then you have the research peptide world. And this is where a Lot of the controversy is being brought up between the compounding pharmacies and the research peptide world.
And the research peptide world are companies like myself, like the Peptique, who offer these types of products. 99% of them are not FDA approved. We are selling them for research purposes only and not for human consumption. We do not talk about dosing protocols, we do not talk about how to reconstitute that sort of thing. And so that's the distinct difference. Now there's also all kinds of regulations that are involved with the different tiers. Okay, you have all the clinical trials and all that stuff
that the big pharma goes through to bring their drugs to the market. It goes through lots of stringent testing. And then you have the compounding pharmacies that have to go through the, the 503A stuff. And it's, it's more, the testing on that is more streamlined. Although I will say I'm not super well versed on exactly what all they do, but I know that they're held to a certain standard and then the research pump type company comes into play where you don't really know. Hopefully you're dealing with a company that has very, it is very
transparent about their testing. They test smaller batches, they test every batch and they're clearly stating that on your website, on their website. So you can kind of see that you're getting a very safe product. But again this is where you hear all the information about they're not safe and that sort of thing. I think they can be very safe. But I think with where the problem lies is that people aren't educated, aren't informed, you don't know what to look for. Also these tests need to be able to be verifiable on the third
party labs website. So you're not just taking the actual company you're buying from and so on and so forth. You've heard me talk about this stuff a million times, I'm not gonna do a deep dive into that. But when we talk about the landscape of research peptides I think it's important to make those distinctions. And so kind of what I wanna focus on today is what is the future of the research peptide world. And this thing has exploded over the last couple of years and
really it's because of the GLP1 movement. So kind of let's break that down so it can kind of make sense to everyone. So when the GLPs first came out and they were being used off label and they were recognizing that they can cause significant weight Loss in people. It became this huge, as everyone knows, this huge trend, very popular. You start seeing it all over social media and all the things. The problem was is that it wasn't readily accessible because
if you're getting something off label, okay, for a pharmaceutical, then you're paying out of pocket for it. And really at the time what was happening is that people were having to pay thousands of dollars, you know, a thousand dollars or more a month in order to receive the peptide. And that's just not sustainable for the average person long term. Okay. Then there became a shortage. Let me back up. Because insurance doesn't cover it if it's used off label. So if you don't meet all the criteria of being diabetic, pre diabetic,
being really unhealthy, then your insurance is not going to cover this. And I even worked with people when I was doing nutritional consulting where they were right on the edge of being diagnosed with type 2 diabetes. And the insurance companies still would not provide access to it. So you really had to be really pretty sick in order for your insurance to cover it. So if your insurance didn't cover it, then you're looking at the out of pocket expense. All right, so what's crazy about that, if you think about it,
it's traditionally how our health care system works is they're not going to help you until you're really, really sick and absolutely have to have one of these medications and they're going to keep you on it and they're not going to deal with any of the other issues that you have. And so it might help with one thing, but it's not going to help with everything. And then you're just stuck in this vicious cycle of going to doctors visits and pharmaceuticals. That's unfortunately the sick care system that we live in and how that works. Okay, well, what happened was, is there became a shortage because
there was such a demand for these and they were proving to be so beneficial to so many people. So they allowed compounding pharmacies to come to fill a void where there was a shortage in supply of these GLPs. And what the compounding pharmacies can do is they could create these at a much more affordable level for the average person. So then you start seeing all the med spas and all those places, start to pick it up, and then you have this whole new audience
of people who are getting on these GLPs, loving these GLPs, seeing what it can do not just in weight loss, but overall metabolic health, systemic inflammation. People have talked about how it helps with cognitive clarity, which again goes back to inflammation. People have talked about how it can help with addiction. I mean, and it just goes on and on and on. And we're learning more and more and more about how these GLPs really have far reaching benefits beyond just weight loss.
So you open this up to this whole new audience and then what happens? Big pharma comes out and says, nope, can't do this anymore. We now have what we need to fulfill the demand. They were looking at it from a standpoint of we're losing all this revenue. We need to get rid of the compounding pharmacies doing this so they can continue to make their money and profit and make all the bazillion dollars off of it. But then what happens is you've just yanked this beautiful peptide away from people that now can't access it through insurance
and don't have a way of getting it through a compounding pharmacy. So what, what are you going to do in that situation? This is where the research peptide space really starts to make a lot of sense for people. Now don't get me wrong, there was a huge explosion in the research peptide space even before all this happened. But this created the perfect storm of circumstances when the FDA and big pharma started coming down really heavily on the compounding pharmacies. Okay? So it created this even bigger void in the market.
And so now we have a target on our backs, right? Because now what they're seeing is, oh well, wait a second, it's like the wild, wild west out there with these research peptide companies. And I'm not going to lie, if you don't know what to look for and you don't know how to purchase safely, then yes, it definitely can be. But it really puts this large target on our back to the point that there was some buzz going around. And some of you may remember this, at the beginning of the year,
the end of last year actually around December, January time that research peptide companies are going out of business and everybody freaked out. And this isn't the first time this has happened. Right? I was getting all these inquiries about it, all this stuff, and you don't know which way is up, you don't know who's being truthful, who's not. It created this storm of people going in and buying all this huge bulk supply inventory to last them forever because they're so afraid it's going to be taken away from them.
Okay, so that happened recently and there is some new legislation that apparently is coming down the pipeline really primarily focused more on compounding pharmacies, not research peptide companies. Now, that doesn't mean that we're not going to get thrown in the mix there or it's not going to put further scrutiny on research peptide companies. But it definitely did not play out the way that some of the, the bigger players were saying that it potentially would. And so the scare tactic, the scare tactics that go out there, you know, can be pretty, feel pretty intense because once you start
down this space and that's what happens, right? Most people, I would say, start with a GLP and then it opens their eyes to what peptides are. They start researching it, you start understanding it, you start seeing all the possibilities and you start going down the rabbit hole of, well, how else can I optimize my health through peptides, okay? And once the cat's out of the bag and Pandora's box is, is open, I think it's really hard to shut that down.
And so I get asked the question all the time, do you think that research peptide companies are going to get banned or they're going to go away? I can't say with a hundred percent certainty. What I will tell you is, is that outside of where the money is for big pharma and the FDA and how they're all in bed together, right, And I may get in trouble for saying that, but whatever, it's just the truth. The GLPs or things like SS31, those are the things that really potentially cause a lot of problem in this space.
I. A lot of companies have already pulled those products from their inventory just to be safe. And so I think you may see more of that happening. What we have to recognize is this is an evolving market. So first we had semaglutide and then we had Tirzepatide. The FDA did come in a couple years ago and really place a heavy hand and started sending warning letters and that sort of thing to a lot of these research peptide companies that they had to cease and desist selling them.
Okay? And a lot of them did. Since then, a lot of those companies have brought it back and still continue to sell it. That's just the honest truth. Well, what's happened now is now we have Retta Truth. So it's not FDA approved yet. And so it's still kind of somewhat in the safe zone, but we know that that's going to be happening soon. So when it is finally officially released through big Pharma, there may be some scrutiny, some tighter scrutiny on that and how the research peptide companies have to handle it.
Let me also say, is there other peptides that are in the works right now that are going to continue to evolve? So I think if one gets taken away, there's already things coming up the pipeline that at least I'm aware of that could easily replace those. So that's the good news is I don't think we're just going to be stripped of the opportunity to purchase these things even under the current climate of what's going on right now. So that is something to you. Remember, I don't think in the grand scheme of things, things like
AOD 9604 or MOT C or those sorts of things, you know, BPC 157, these are not things that are going to ever really go through FDA approval. And so they don't. No one cares about those. Right. Because that's not where the money is. And so I think that space is relatively safe because at the end of the day, what they care about is money and making sure they're getting what they feel like is due to them. And if we're staying out of that lane, then that essentially
removes the target off our backs when it comes to these sorts of things. Here comes the next question. Because recently, as most of you know, RFK came out and said on Joe Rogan's podcast that he was pushing to have, I think about 14 peptides taken off the restricted list, which would open it up for compounding pharmacies to start, start offering them again. That's the first thing that's happening, and it's not a hundred percent, but everything that I've read suggests that this is a
real possibility for, if not all of them, most of them. And so what that is going to do, assuming that that does happen, is that's going to allow someone to go to their doctor, assuming their doctor understands the peptide space, which a lot of them don't. And doctors are going to be able to offer these things, and med spas that have doctors that work for them will be able to offer these things where you can pay to go see a doctor, get a prescription
and have that prescription filled. And of course that's going to come with a price. But the research peptide space isn't for everyone. So it's going to open up the world of peptides to more people that really want that assurance, that don't feel comfortable going through the research peptide space, but still want access to some of these things, to try some of these things. It's going to open these peptides up to a new audience. So I think it's only going to get more and more popular.
The other thing I will say about that, what often happens and when I'm speaking with people is that people get started that way. They soon realize that it's not affordable long term, but they've fallen in love with the peptide world and then they start really diving into the research peptide space. So you do see a lot of people move from the compounding pharmacy space over to the research peptide space. And once they get a certain comfort level with it, not always, but a lot of the time. So I think you're going to continue to see this market grow.
I think the problem with that is that now that it's being open to compounding pharmacies and doctors, it's going to put an additional target on our back. So we're going to get even more scrutinized, which is not necessarily a bad thing. Okay. I'm hoping a lot of the bad players that don't play right will start to get out of the industry. That is the hope. And I won't go into too much detail about this right now, but the peptique and myself in particular, we are working right
now to put some things into place to really set us apart. So anyone that may be interested in access of research peptides can fill with a hundred percent certainty that what they're getting is a very clean, pure, safe product. Okay. So more to come on that later, but I do think it's gonna do a little bit of both. It's gonna open up people to peptides. It's also gonna potentially put a bigger target on our bat. Because now what's going to happen is the doctors and the compounding
pharmacists for the most part, are gonna come in and say, do not use research peptides. They're not safe. They're all these bad things because now they can offer them. So now they have skin in the game, and so now it matters. So I do expect to hear and feel some backlash regarding that. All right. The other thing that I think is interesting is that Eli Lilly, for one, saw the gap that they were missing with the not offering the peptides to people that didn't qualify for it through insurance.
And they've actually opened up their own pharmacy. I can't think of the name of it right now where you can buy directly from Eli Lilly. You have to have a doctor prescription for it. Okay. So it doesn't come without its hurdles, but they're offering single vial dose for people to come in and buy At a reduced cost. Now is it going to be reduced as much as buying through research peptide company? No. And as far as I know, there is no plans right now for the GLPs coming
back to the compounding pharmacies. So this is to bridge that gap between those two. And so that is also happening because the, you know, the pharmaceutical companies realized how much potential revenue they were losing by not having some sort of solution for this. That's just how popular they got. Another reason why they're growing so big. And again, there is a space for people that that's really what they want. And I think that's great because if that works for you and, and you can benefit from all the health benefits from it and that's
the route that you choose to go, more power to you. Because the whole point in all of this stuff is to provide health and wellness preventative type of care. Right? And that's what these things do. That's why I'm so obsessed with them. That's why I got into this space to begin with. All right, so the other question that I got that I think freaked a lot of people out recently is surrounding Peptide Sciences, which is one of the OGs, maybe the OG in the United States, at least for research peptide companies.
People have asked me so much about this and is this an indication of what's going to be happening unilaterally across the board with research peptide companies? And the answer is again, I don't know. I can tell you what I know today with the information that I have today and what my gut tells me on what may or may not happen. But let me say this, this has been a wild ride. Starting the pettic and getting into this space, I've learned a ton. I think I went into it a bit naively. That being said, it's a roller coaster.
So every day something changes and we're having to navigate through this. But I was just shocked when I heard this. I had not heard any chatter of this happening. I think the general consensus is that nobody really did. I'm sure there were some few people behind the scenes that knew this was coming. I don't think they just woke up one morning and shut down. I, I, the true and the truth is I don't know what happens. I think there's a lot of speculation going on. My understanding is that this was not anything to do with any kind of FDA regulation coming down on them.
That could be wrong. But I do know that those things are usually made public knowledge. So had they been sent letters or warnings or things like that. You can get on the fda, FDA website and see that information. And to my knowledge, there is no record of that. So I don't really think that that was it. I've also heard, you know, this space is getting tighter and tighter and in regards to the type of regulatory control and scrutiny that we're under. And the owner had been in this in a long time, and my understanding
that he is a big entrepreneur and that he may just been like, I'm moving on to different things. I want out of this also. I think it's probably been less profitable. They were one of the companies that pulled their glp. They have a lot more competition in the market. They were on the more expensive side. So that was squeezing their profit margin quite a bit. So I could see it being honestly a combination of those two and just wanting to move on to different things and get out of this space. They may come back, and I've seen a lot of companies do this. They may pivot, come back under a telemed platform.
I. I'm hearing a lot of rumors of some other companies doing that, and we may see them come back again in just a different format. I don't really know. But it is an indication that things are shifting and they do shift fast. What does that mean overall for the research peptide industry? I think the key is staying compliant and being able to pivot very quickly when a roadblock gets put in our way. And so those are the things that I want to go into briefly next, just because I feel like there's a lot of bad information
out there about why some of these things are happening. So those of you that have followed me for any length of time have been supporters of the peptide. You have noticed probably in the last few months that we've had a heck of a time with our credit card processing. We literally woke up one morning and it was a shutdown. And not only did they shut us down, they. They kept all the money that they owed us and chalked it up to us owing them fines for the purchases that they did on our behalf,
which is super frustrating. Let me be clear. I was very, very frustrated at the beginning. And now I'm just learning to live in this space and realize that it's just part of being in this space. And so I'm. I'm not complaining, at least not anymore. I'm getting used to it and having to pivot quickly and recognizing if this is a space that I want to stay, in, which it is. These are the things that I'm going to be up against, but I want to kind of break this down for you so you understand exactly what's going on and what you're going to see more of in this space.
So once we got thrown out of traditional credit card processing, we had to move to what's called a high risk processor. And we are considered high risk because the credit card companies and the banks that back them see us as a volatile industry. So we're under regulatory scrutiny by government entities like the fda. Policies could change at any given time. We're at a higher risk of chargebacks, okay, Meaning people either fraudulently purchasing or coming in and saying, well, I
regret my purchase and I want my money back and things like that, which puts the credit card companies at risk. And because of all these things, we cannot get traditional credit card processing. So when we get thrown into the high risk processor, a bunch of things happen. Has to be funneled through a different system. And the most popular ones right now, what they do is they convert your US Dollars into cryptocurrency and then you're actually purchasing in cryptocurrency. The problem with these programs is that they often have
a high failure rate, so you're often get declined and they oftentimes will have a limit, like a $300 limit per purchase, which can be super frustrating if you're wanting to purchase more than that. The biggest issue that we've come up against though is this, what's called KYC authorization, that's know your customer. This is to help protect not only you, the consumer, but also protect the credit card merchant. And it puts you through a series of questions and authorizations
and lots of times often gets through an even more invasive process where they take a picture of your driver's license and they match that to your face so they can confirm your identity. And in some cases too, they even go as far as asking for your Social Security number. Now I realize most people don't want to give out that information when trying to purchase a peptide. So it causes a big hurdle in our industry. And the truth is because of this, we just took it down altogether. Because I completely understand that we are working on
a new system that won't do that. But we are very limited in what we can offer. And this is happening across the board with most research peptide companies. And even if you have a vendor that you work with that hasn't happened to you yet, rest assured, it's probably will happen sometime in the near future. And we're constantly trying to figure out how to different ways of payment. So that's why you'll see Zelle Echeck E Debit. And then we have this other credit card, it's called a credit
card ramp processor that we are using to try to give you as many payment options as possible. But just know we. The last thing we want to do is make it a hurdle for you to check out. But this is the way that things are going. So it is going to be adjustment and things you're going to have to get used to if you want to continue purchasing research peptides. So I kind of wanted to explain that, but also lay out there the understanding of what this research peptide space is up against.
That's one hurdle. Other thing I will say is that the rates they charge us are anywhere from 12 to 20% per transaction. So that, that really prohibits a lot of research peptides companies from staying in business if they can't pivot quickly. So we've got that. That's going to be more and more. When we talk about the future of this space, it's going to be more and more of a hurdle, not just on the business owner's end, but also on the consumer's end to find a safe, comfortable, accessible
way to pay. Okay, then I think we're also, like we talked about, we're going to continue to see more and more regulatory scrutiny. So the key is to be able to always have the ability to pivot and stay informed in these things and then to stay above board with how you do business, how you do testing, all those sorts of things. That's critically important. And we have to be able to understand what's coming down the regulatory pipeline, be able to present that to you, the consumer,
the audience in this case, so you can make informed decisions on how you want to move forward in this space as well. Lots of hurdles, lots of big targets on our backs. But I don't honestly see this space going away. I see it ever evolving as more and more possibilities come into the research peptide space that continue to help us evolve and live the best, healthiest, optimized life that we can. And so on that note, you know, we have a lot of exciting things
coming up the pipeline because that's what we're trying to do. We're trying to present as many products as we can that you guys want. Also trying to stay away somewhat from those. Those particular research compounds that might put a target on our back. So we're trying to find a balance in all of this. But we do have some exciting things coming to The Peptique. And so I wanted to. When we talk about the future, I know I keep talking about the hair serum, the AHKCU hair serum that is coming up, that.
That is going to be coming in the lineup soon. We've just had a hard time getting the formula just like we want it, and we don't want to bring anything that we wouldn't personally use to you. So that's in the works. Hopefully it'll be soon. We have a whole line of the intranasal applications of a lot of the peptides, where you can buy them in a bundle coming up as well. I think that's probably about four weeks out. And we have some Dihepta capsules, which, um, I plan on doing a episode on Berry soon.
That's one I'm excited about. And those are just a few. So we're bringing a lot of fun, interesting things that I think y' all will be excited to try at the end of the day. I know I talk about the Pepti. There are so many different vendors out there, and there are good ones or bad ones. And of course I'd love for you to buy from the Pepti. That's not why I'm doing this. It's not why I did this episode. It's more of an informative, so you understand the landscape of the space that's going on. Also knowing that wherever you buy from, just make sure that.
That you're doing all your due diligence to make sure you're getting the best, cleanest product possible. Because the other thing, if people start getting really sick or having adverse reactions and all that stuff, it's going to be get out there super fast and possibly cause bigger ramifications if people aren't doing that and people are having adverse reactions because they're not doing their due diligence before they purchase. So that's the main reason why I wanted to throw this all out there. And so, yeah, starting next week, I'm gonna get back into more
because I know you guys like that. Of the let's talk about this peptide or this stack, and let's talk about what it does, how you can use it and that sort of thing. Know that's what you really love. But lately there's been so many Q&As that I've gotten, and particularly on this topic, I wanted to do an episode that really specifically spoke to itch. And let's see what else before I let you go. Reminder. If you're a woman and you are interested in peptides, whether you're getting started and you're a novice at it, or whether you're an
expert at it. Go join the Women's Peptide Collective. It's a free group on the school platform. I will put a link in the show notes. I learned so much from the ladies there and I get on there usually at least once a day to try to answer any questions that have come in. Um, I post Peptide Spotlights every week where I really do a deep dive on a particular peptide. So you have that information at your fingertips. And yeah, it's a great space. So if you're interested in that, go do that. I've also mentioned this a few times. I have updated the Peptide guide, so if you have one like from
a few months ago, email me. I will send you the new one. It has a lot more information on it. It's a lot more detailed. I think that you will really like it. It's totally free. You just email it. Email me and I'll shoot it over to you. Please share this podcast with anyone and everyone that you think might be interested in it. That helps me to keep doing what I'm doing. On that note, I know I sound redundant and I say this every time, but thank you, thank you, thank you for all your support. I can't tell you how much it means to me. I get super kind emails from a bunch of you every week and I love
seeing those. If you email me with a question, I will do my best to respond to you quickly. If I don't respond, bug me again. That just means it may have got missed in the sea of emails that happens sometimes. I think that's it. So I'll close out like every time. And until next time, have a blessed day everyone.
Our new topical line is about to launch! Sign up for notifications and special discounts here: https://thedermatique.com/ Follow us: Instagram: @thedermatiqueofficial. TikTok: @the.dermatique Join our free community,...
Our new topical line is about to launch! Sign up for notifications and special discounts here: https://thedermatique.com/ Join our free community, The Women’s Peptide Collective, click the Skool link to become a member...
Join our free community, The Women’s Peptide Collective, click the Skool link to become a member and to connect, learn, and collaborate. https://www.skool.com/womens-peptide-collective-9663 Go to https:thepeptique.com/...
Join our free community, The Women’s Peptide Collective, click the Skool link to become a member and to connect, learn, and collaborate. https://www.skool.com/womens-peptide-collective-9663 Go to https:thepeptique.com/...
Join our free community, The Women’s Peptide Collective, click the Skool link to become a member and to connect, learn, and collaborate. https://www.skool.com/womens-peptide-collective-9663 Go to https:thepeptique.com/...